Suven Life Sciences secures product patents in Mexico, New Zealand

07 Aug 2018 Evaluate

Suven Life Sciences has secured one product patent from Mexico and one product patent from New Zealand corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2030 and 2036 respectively.

The granted claims of the patents include the class of selective H3 and 5-HT4 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia and sleep disorders like Narcolepsy etc.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

Suven Life Sciences Share Price

167.45 4.40 (2.70%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 901.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×